Perma-Pipe and Welspun Announce Memorandum of Understanding to Establish Pipe Manufacturing and Coating Facilities in Jordan

 THE WOODLANDS, Texas - Tuesday, 01. September 2026 AETOSWire  

Strategic Partnership to Establish Integrated Pipe Manufacturing and Coating Capabilities to Support Water, Oil & Gas, and Infrastructure Projects in Jordan and the Levant Region.

(BUSINESS WIRE) -- Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a global leader in engineered pipe solutions specialising in anti-corrosion coatings, insulation solutions, containment systems, custom fabrication and leak detection, today announced that it has signed, together with Welspun Corp Limited (“Welspun”), a Memorandum of Understanding (“MOU”) with the developers of Jordan’s National Water Carrier Project and the Government of the Hashemite Kingdom of Jordan to advance the development of pipe manufacturing and advanced coating facilities in Jordan. The parties intend to establish a joint venture to support the development and operation of these facilities.

Transaction Description

Under the terms of the MOU, Perma-Pipe and Welspun have partnered to establish an integrated pipe manufacturing and coating platform in Jordan capable of serving major water, oil and gas, energy, and infrastructure projects in the Kingdom and across surrounding regional markets.

The partnership is expected to bring together Welspun’s large-diameter steel pipe manufacturing capabilities and Perma-Pipe’s expertise in anti-corrosion coating systems designed to protect pipelines from corrosion and extend service life, engineered piping solutions and project execution expertise.

Next Steps

Perma-Pipe, Welspun, and the project developers are engaged in the technical, commercial, financing and regulatory requirements associated with the project, including facility design, manufacturing capacity, coating technologies, market requirements and applicable approvals. Additional details regarding Perma-Pipe’s investment in the JV, ownership structure, capacity, and project timeline will be announced as the project progresses and definitive agreements are completed.

Strategic Regional Platform

The partnership is intended to create a strategically located regional manufacturing hub that can support large-scale infrastructure programs, strengthen regional supply chains, increase local value creation and develop skilled technical capabilities in Jordan. Over time, it could also support infrastructure development and reconstruction requirements in Syria, Lebanon, Iraq and Gaza, as well as potential future opportunities associated with the development and rerouting of regional oil and gas infrastructure toward the Port of Aqaba.

Saleh Sagr, President and Chief Executive Officer of Perma-Pipe, commented:

“Our proposed investment in Jordan is consistent with Perma-Pipe’s strategy of expanding its global manufacturing and coating footprint in strategically important markets where long-term infrastructure investment is expected to create attractive growth opportunities. Jordan’s geographic position is particularly important to our vision, offering a manufacturing base in the Kingdom that can serve as a gateway to markets across the Levant and broader Middle East and provide a platform from which to tap the significant infrastructure investment we expect in the region over the coming years.

“Perma-Pipe and Welspun bring highly complementary capabilities to this opportunity, creating a strong foundation for an integrated manufacturing platform that can serve customers from within the region. The proposed platform would further extend Perma-Pipe’s ability to provide localized manufacturing and coating solutions while improving customer responsiveness, strengthening supply-chain resilience.

“We are pleased to be working with Welspun and the project developers on this initiative and appreciate the support of the Government of Jordan. We believe this project has the potential to become an important regional manufacturing center and contribute meaningfully to Jordan’s industrial development, supply-chain capabilities and long-term economic growth.

“We would also like to express our sincere appreciation to the Jordanian Government for their support and engagement in helping facilitate this important opportunity. Their continued commitment to strengthening commercial ties between the United States and Jordan and supporting American companies pursuing strategic international investments has been instrumental in advancing this initiative,” Mr. Sagr concluded.

Vipul Mathur, Managing Director and Chief Executive Officer of Welspun Corp Limited, commented:

“This JV with Perma-Pipe aligns with investments we are making in onshore and offshore oil and gas projects, water infrastructure development, reconstruction opportunities across the Middle East, and emerging hydrogen and carbon capture utilization and storage initiatives, that are expected to support sustained pipeline demand.

“The combination of our pipe manufacturing expertise and Perma-Pipe's innovative, advanced coating and engineered solutions capabilities can create a differentiated offering as we seek to build stronger customer relationships. We look forward to working with Perma-Pipe, the project developers and the Government of Jordan to advance this initiative and develop a long-term industrial presence in the Kingdom.”

H.E. Eng. Raed Abu Soud, Minister of Water and Irrigation of the Hashemite Kingdom of Jordan, said:

“Jordan welcomes strategic investments that strengthen our national manufacturing capabilities and support the development of critical water infrastructure. The Government, with directions of HM King Abdullah, are supporting these significant investments to strengthen our water security among other sectors, and these require reliable, high-quality infrastructure together with strong local supply-chain capabilities. We welcome the proposed partnership involving Perma-Pipe and Welspun, which represents an important opportunity to establish advanced pipe manufacturing and coating capabilities in the Kingdom, and to increase local participation in major infrastructure projects.”

Supporting Jordan’s Water Security and Infrastructure Development

Jordan’s National Water Carrier Project (“NCP”) is one of the Kingdom’s most significant strategic infrastructure initiatives, designed to enhance long-term water security and address growing water supply challenges. The project is expected to transport desalinated water from the Gulf of Aqaba to communities across Jordan through a major pipeline network and associated water infrastructure.

The development of local pipe manufacturing and advanced coating capabilities is intended to support the NCP’s substantial infrastructure requirements while creating a long-term industrial platform capable of serving future water, energy and infrastructure projects in Jordan and the Levant region. Beyond the NCP, the planned facilities are expected to position the future joint venture to pursue additional opportunities in Jordan and across regional markets.

About Perma-Pipe International Holdings, Inc.

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) is a global leader in engineered piping and corrosion protection solutions. The Company provides pre-insulated piping systems, leak detection systems, anti-corrosion coatings and related engineered products and services to customers across the energy, district energy, infrastructure, industrial, Oil & Gas, water transmission, and other critical infrastructure markets.

Perma-Pipe operates manufacturing and service facilities across North America, Middle East, North Africa, India and other strategic markets, enabling the Company to serve customers globally while providing local manufacturing and engineering capabilities.

For more information, visit www.permapipe.com.

About Welspun Corp Limited

Welspun Corp Limited is a flagship company of the Welspun Group and a leading global manufacturer of large-diameter line pipes. Welspun offers a broad range of line pipe products, including LSAW, HSAW, HFW and HFIW pipes, as well as specialised coating, double jointing and bending capabilities. Its products serve major oil and gas, water and infrastructure applications.

Vipul Mathur is Managing Director and Chief Executive Officer of Welspun Corp Limited.

For more information, visit www.welspun.com

Forward-Looking Statements

Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) the impact of a health pandemic on the Company's results of operations, financial condition and cash flows; (ii) fluctuations in the price of oil and natural gas and its impact on the customer order volume for the Company's products; (iii) the Company's ability to comply with all covenants in its credit facilities; (iv) the Company’s ability to repay its debt and renew expiring international credit facilities; (v) the Company’s ability to effectively execute its strategic plan and achieve profitability and positive cash flows; (vi) the impact of global economic weakness and volatility; (vii) fluctuations in steel prices and the Company’s ability to offset increases in steel prices through price increases in its products; (viii) the timing of order receipt, execution, delivery and acceptance for the Company’s products; (ix) decreases in government spending on projects using the Company’s products, and challenges to the Company’s non-government customers’ liquidity and access to capital funds; (x) the Company’s ability to successfully negotiate progress-billing arrangements for its large contracts; (xi) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xii) the Company’s ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (xiii) the Company’s ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xiv) reductions or cancellations of orders included in the Company’s backlog; (xv) the Company's ability to collect an account receivable related to a project in the Middle East; (xvi) risks and uncertainties related to the Company's international business operations; (xvii) the Company’s ability to attract and retain senior management and key personnel; (xviii) the Company’s ability to achieve the expected benefits of its growth initiatives; (xix) the Company’s ability to interpret changes in tax regulations and legislation; (xx) the Company's ability to use its net operating loss carryforwards; (xxi) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company’s percentage-of-completion revenue recognition; (xxii) the Company’s failure to establish and maintain effective internal control over financial reporting; and (xxiii) the impact of cybersecurity threats on the Company’s information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at https://www.sec.gov and under the Investor Center section of our website (http://investors.permapipe.com).

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901617785/en/

Permalink

https://www.aetoswire.com/en/news/0109202656991

Contacts

Saleh Sagr, President and CEO

Perma-Pipe Investor Relations

investor@permapipe.com

847.929.1200

Global Tech Sales Forecast to Reach $1.4 Trillion in 2026, Even as 56% of Consumers Delay Purchases, NIQ Finds

CHICAGO - Tuesday, 01. September 2026

Global study finds price-sensitive shoppers will still pay more when products deliver clear, lasting benefits

(BUSINESS WIRE) -- Global sales of consumer technology and durable goods are forecast to reach $1.4 trillion in 2026, up 5.1% year over year, even as 56% of consumers say they have delayed a technology purchase because of price or while waiting for a discount, according to new research from NIQ (NYSE: NIQ), the Official Global Insights Partner of IFA.

Released ahead of IFA 2026, which kicks off in Berlin on Sept. 4, 2026, NIQ today released its annual “State of Tech & Durables” report. Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified examines how years of economic volatility have transformed technology purchasing behavior and what manufacturers and retailers must do to remain competitive.

Key findings include:

Global T&D sales are forecast to reach $1.4 trillion in 2026, up 5.1% year over year

63% of T&D consumers exhibit high price sensitivity

60% prioritize brands that offer "good value for money"

56% have delayed a tech purchase because a product was too expensive or they were waiting for discounts

Consumers rank durability, quality, convenience, and trust ahead of affordability when defining value

Drawing on a survey of 17,000 adult consumers across 17 markets and NIQ's global sales intelligence, the report finds that consumers are no longer evaluating purchases with a simple question of affordability in mind. Instead, they are increasingly asking whether a product will continue to feel worthwhile long after the purchase has been made. This behavioral shift is influencing premiumization trends, replacement cycles, innovation priorities, and pricing strategies across technology categories.

"Consumers still want innovation, but they increasingly require a compelling reason to buy,” said Perry James, Global Head of Tech & Durables at NIQ. “Today’s buyers are asking, ‘Will this purchase still feel worth it six months from now?’ The brands that grow in 2027 will be those that make value obvious, reduce uncertainty, and help consumers confidently justify their purchase decisions.”

Consumer Tech Trends 2027 reveals that while consumers remain highly price-sensitive, they’re still willing to pay premium prices when products deliver meaningful benefits. Categories such as AI-enabled PCs, premium smartphones, advanced vacuum cleaners, and larger-screen televisions continue to outperform broader category averages when consumers clearly understand the advantage being offered.

NIQ, the Official Global Insights Partner of IFA, will present findings from this report and other Tech & Durables trends at the IFA 2026 conference on Sept. 4, 2026. To learn more about the report, visit niq.com/consumer-tech-trends-2027.

FAQs

What is Consumer Tech Trends 2027?

Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified is NIQ's annual State of Tech & Durables report. Based on a survey of 17,000 consumers across 17 markets and NIQ's global sales intelligence, the report examines how changing consumer attitudes toward value, affordability, and technology purchases are reshaping the consumer technology market.

What is the report's main finding?

The report finds that consumers are increasingly evaluating technology purchases based on long-term value rather than affordability alone. Shoppers are asking whether a product will continue to feel worthwhile after purchase, influencing how they evaluate features, pricing, and brands.

Why are consumers delaying technology purchases?

According to the report, 56% of consumers have delayed a technology purchase because the product was too expensive or because they were waiting for a discount. Price sensitivity remains high, even as consumers continue to seek innovation and performance.

How price-sensitive are today's technology consumers?

The report finds that 63% of consumers exhibit high price sensitivity, while 60% prioritize brands that offer good value for money. This suggests consumers are carefully weighing purchase decisions and looking for clear evidence that products justify their cost.

If consumers are price-sensitive, why are premium products still growing?

Consumers remain willing to pay premium prices when products deliver meaningful and clearly understood benefits. Categories such as AI-enabled PCs, premium smartphones, advanced vacuum cleaners, and larger-screen televisions continue to outperform broader category averages when consumers perceive strong value.

What do consumers consider when defining value?

The report finds that consumers rank durability, quality, convenience, and trust ahead of affordability when assessing value. Increasingly, consumers are looking beyond price alone and evaluating the total benefit a product provides over time.

What do these findings mean for manufacturers and retailers?

Technology brands must do more than introduce new features. Success increasingly depends on helping consumers understand the value of innovation, reducing uncertainty, and clearly communicating the long-term benefits of ownership.

What is the outlook for the global technology market?

NIQ forecasts global Tech & Durables sales will reach $1.4 trillion in 2026, representing 5.1% year-over-year growth. The report suggests future growth will be driven by products that clearly demonstrate value and help consumers confidently justify purchases.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

© 2026 Nielsen Consumer LLC. All Rights Reserved.

All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

Forward Looking Statement

This press release about NIQ’s Consumer Tech Trends 2027 report on global consumer technology and durables sales may contain forward-looking statements regarding anticipated consumer technology purchasing behavior, global T&D sales forecasts, category growth trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as ‘forecast,’ ‘will,’ ‘suggests’ and similar expressions are intended to identify forward-looking statements.

These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

#NIQ-General

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901758503/en/

Permalink

https://www.aetoswire.com/en/news/0109202656980

Contacts

Media Contact: media.relations@nielseniq.com

Mary Kay Unveils New Global Brand Platform – Beauty Is More Beautiful Shared™ – Reclaiming Beauty as a Shared Experience

DALLAS - Tuesday, 01. September 2026 AETOSWire  

With Largest Consumer-Facing Campaign In Company History Mary Kay Enters Its New Era Of Reach And Impact

 

(BUSINESS WIRE)--Today, Mary Kay Inc., the iconic beauty and entrepreneurship brand founded by the bold visionary Mary Kay Ash, announced Beauty Is More Beautiful Shared™, its largest-ever global consumer-facing campaign and a long-term brand strategy designed to drive its next era of growth. Launching across 40 markets worldwide, the campaign reintroduces Mary Kay to a new generation of consumers by celebrating a timeless truth at the heart of the brand: Beauty Is More Beautiful Shared™ and bridging the love for Mary Kay across generations.

“Beauty Is More Beautiful Shared™ is a reflection of who we are and what we have always stood for: women supporting women,” said Ryan Rogers, Chief Executive Officer of Mary Kay Inc. “As we enter our next era of growth, we are celebrating and empowering every Mary Kay woman, from our Independent Beauty Consultants to customers, expanding our reach and impact and bringing our promise of confidence, opportunity, and human connection to life in bold, relevant, and compelling new ways.”

Through Beauty Is More Beautiful Shared™ Mary Kay directly addresses the shift in beauty, tapping into a profound cultural longing for community and connection that the world, and generations of women, are feeling more than ever. The campaign champions connection, sisterhood, and community in an increasingly digital world, reinforcing Mary Kay's unique point of view and modern relevance as a beauty brand built not only on products, but on relationships.

“In a world where beauty has often resonated as a solo act, we're reclaiming beauty as a shared experience, celebrating the power of sharing, supporting, and uplifting one another. Beauty Is More Beautiful Shared™ brings the enduring power of womanhood and shared connection into the way Mary Kay approaches beauty,” said Dr. Lucy Gildea, Chief Brand and Scientific Officer of Mary Kay. “Through this master brand campaign, we are sharing the emotional connection and timeless purpose at the heart of our brand with consumers around the world, celebrating the transformative power of our iconic products and the difference our brand makes in women’s lives and communities. This campaign is an invitation to rediscover what has always made Mary Kay different, and to experience the beauty of what’s possible when we share it.”

Beauty Is More Beautiful Shared™ global campaign was developed in partnership with Grey, through an all women-team bringing together a modern creative vision and Mary Kay's enduring heritage to shape the next chapter of the brand.

“Beauty Is More Beautiful Shared™ elevates Mary Kay as the contemporary, confident brand it is, not just in strategic vision, but in its visual execution,” said Agnes Fischer, U.S. Chief Executive Officer of Grey. “Working alongside an A-list director from the next generation, Olivia De Camps, we’ve built a creative narrative that reveals a powerful truth about Mary Kay. The campaign meets today’s women where they are, re-igniting the iconic Mary Kay brand and making it unmistakably relevant.”

Beauty Is More Beautiful Shared™ was intentionally designed to support the success of Mary Kay Independent Beauty Consultants. With a message that amplifies community and transformation, this bold campaign will broaden awareness and foster a desire to purchase Mary Kay products and to connect with Independent Beauty Consultants through their personal digital storefront at Mary Kay.

GLOBAL ACTIVATIONS: Beauty Is More Beautiful Shared™ will be powered through a comprehensive media mix tailored to meet the next generation of beauty and community lovers where they are, further amplifying the campaign's reach and impact.

The campaign rollout includes an effective blend of online amplification through digital platforms, social media, influencer partnerships, and “real world” bold, out-of-home placements and events.

A wave of high visibility, unmissable, experiential consumer events designed to bring Gen Z together in real life will kick off in New York this month, engaging a global community across 40 markets from Brazil, Mexico and China to Kazakhstan, the Czech Republic and more.

Topping The Global Charts:

Mary Kay ranked #8 out of 5,500 brands on Forbes’s 2026 Best Brands for Social Impact1 moving up from stellar #9 achieved in 2025. Mary Kay is the only beauty brand in the Top 15.

Mary Kay ranked #2 on Forbes 2026 Best Customer Service list moving up from #93 in 20252. Mary Kay is the only Beauty brand in the Top 15 and the only direct-selling company in the Top 50.

Mary Kay is named to Happi’s Top 50 U.S. Companies 2026 Report, cinching Mary Kay Ash’s favorite number 13 ranking3.

Discover Mary Kay’s Beauty Is More Beautiful Shared™ Campaign:

Watch the Campaign Film here.

Experience the Campaign Creatives here.

Learn More About Campaign Film Director Olivia De Camps.

ABOUT MARY KAY

For more than 60 years, Mary Kay has empowered generations of women around the world to discover beauty together, build meaningful futures and find a community of women who celebrate one another. Founded by Mary Kay Ash in 1963, the global beauty company has connected women across 40 markets through innovative skincare, color cosmetics, fragrances, and wellness products. Mary Kay transforms purpose into action by advancing causes that support women and families, investing in scientific innovation, and working toward a more sustainable future. At its core, Mary Kay is dedicated to enriching women's lives and creating opportunities for women to thrive together. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn.

ABOUT GREY

Grey’s mission is to create Famously Effective ideas that move people, businesses, and the world forward, harnessing the power of creativity to solve business challenges and drive growth for some of the world’s most influential brands and companies, including Procter & Gamble, Volvo, Haleon, Circle K, and The Coca-Cola Company. That commitment to effectiveness has earned Grey a Grand Effie in every market where it operates. Grey was recognized as a 2025 Fast Company World Changing Ideas winner and earned 26 Lions at the 2026 Cannes Lions International Festival of Creativity, contributing to Ogilvy’s Network of the Year honors. Newsweek also named Grey a Top 100 Global Most Loved Workplace in 2024 and one of America's Greatest Workplaces for Women and Professional Services in 2025. Grey is part of WPP, the trusted growth partner for the world's leading brands. Powered by exceptional talent and our agentic marketing platform WPP Open, WPP unites cutting-edge media intelligence and data solutions, creativity, production, enterprise solutions and expert strategic counsel.

____________________

1

Alan Schwarz (March 17, 2026). Forbes - Best Brands For Social Impact 2026. https://www.forbes.com/lists/best-brands-social-impact/

2

Alan Schwarz (October 14, 2025). Forbes - Best Customer Service 2026. https://www.forbes.com/lists/best-customer-service/

3

Happi’s Top 50 Report. https://www.happi.com/top-companies-reports/top-50-us-companies/

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901735460/en/

Permalink

https://www.aetoswire.com/en/news/1092026569955

Contacts

Mary Kay Inc. Corporate Communications

newsroom.marykay.com

972.687.5332 or media@mkcorp.com

منصة MEX Exchange، التابعة لمجموعة MultiBank Group، تعلن عن تعيين قياديين جديدين في الإدارة العليا

دبي، الإمارات العربية المتحدة - الثلاثاء, 01. سبتمبر 2026

• تعيين David Ogg نائبًا لرئيس مجلس الإدارة وBrian Andreyko رئيسًا تنفيذيًا.

(BUSINESS WIRE)-- أعلنت MEX Exchange، منصة التداول الإلكتروني المؤسسي التابعة لمجموعة MultiBank Group، عن تعيين قياديين جديدين في الإدارة العليا، حيث تمت ترقية David Ogg إلى منصب نائب رئيس مجلس الإدارة، وترقية Brian Andreyko إلى منصب الرئيس التنفيذي. ويعزز هذان التعيينان قيادة الشركة في غمار مواصلتها تطوير منصة التداول الإلكتروني المؤسسي التابعة لها.

يتمتع David Ogg بخبرة ثرية تزيد على أربعة عقود في مجال تداول العملات الأجنبية وتقنيات التداول، ويحظى بتقدير واسع في صناعة تداول العملات الأجنبية المؤسسية، حيث يُعرف بلقب "أبو شبكة الاتصالات الإلكترونية (ECN)". وقد أسس شركة HotspotFX في عام 1999، وهي أول شبكة اتصالات إلكترونية مؤسسية لتداول العملات الأجنبية، قبل أن يؤسس لاحقًا LavaFX وOgg Trading. كما قد شملت مسيرته المهنية أيضًا تولي مناصب قيادية في Credit Suisse وLehman Brothers وHSBC وDresdner Kleinwort Benson، إلى جانب تعاونه مع Bloomberg وCitibank في مجال حلول تداول العملات الأجنبية المؤسسية. أضف إلى ذلك، أنَّ اسمه قد أُدرج في قاعة مشاهير Profit & Loss.

 وتعليقًا على تعيينه، صرح David Ogg، نائب رئيس مجلس إدارة MEX Exchange، قائلاً: "شهد سوق تداول العملات الأجنبية المؤسسي تطورًا كبيرًا على مدى العقود الماضية، غير أنه لا يزال هناك مجال واسع للابتكار في آليات الوصول إلى السيولة ومواءمة أوامر التداول وتنفيذ الصفقات. ونحن في MEX Exchange، ينصب تركيزنا على الجمع بين الخبرة العميقة في الأسواق والتكنولوجيا المتقدمة لبناء منصة تداول مؤسسية تلبي المتطلبات المتطورة للمشاركين في الأسواق على مستوى العالم. من جانبي، أتطلع إلى دعم التوجه الإستراتيجي للشركة في منصبي الجديد نائبًا لرئيس مجلس الإدارة."

يتمتع Brian Andreyko بخبرة ثرية تزيد على 30 عامًا في مجال التكنولوجيا المالية والأسواق المؤسسية، وله سجل حافل في تأسيس شركات التداول الإلكتروني وتوسيع نطاق أعمالها وقيادتها. وقد شغل سابقًا منصب الرئيس التنفيذي لقسم شؤون العمليات ورئيس الموظفين في Currenex، كما شغل منصب نائب الرئيس التنفيذي ورئيس EBS في ICAP. كما شغل منصب الرئيس التنفيذي في MakoFX/Liquidity Pool، ومنصب الرئيس التنفيذي لقسم شؤون الأعمال في TradAir، وقد تم الاستحواذ على كلتا الشركتين لاحقًا.

 صرح Brian Andreyko، الرئيس التنفيذي في MEX Exchange، قائلاً: "تمتلك MEX Exchange فرصة واضحة لتقديم عرض متميز إلى سوق التداول المؤسسي. وستكون أولى أولوياتي بصفتي الرئيس التنفيذي هي توظيف خبراتنا في التكنولوجيا والأسواق لتطوير منصة قابلة للتوسع تدعم عنصري السرعة والكفاءة وتقدم تجربة متميزة في عالم تنفيذ الصفقات، وتجمع بين المشاركين من الأسواق الناشئة والأسواق العالمية. ثم إنني أتطلع إلى العمل عن كثب مع David وفريق العمل الأوسع نطاقًا في غمار انتقالنا إلى المرحلة التالية من نمو الشركة."

يأتي هذان التعيينان في إطار مواصلة MEX Exchange الاستثمار في قياداتها وقدراتها المؤسسية، بما يدعم طموحها لتعزيز حضورها في أسواق التداول الإلكتروني العالمية.

 نبذة عن MULTIBANK GROUP

 تُعدّ MultiBank Group، التي تأسست في كاليفورنيا بالولايات المتحدة في عام 2005، مؤسسة رائدة عالميًا متخصصة في مجال المشتقات المالية، إذ تقدم خدماتها إلى أكثر من مليوني عميل في 100 بلد، ويتجاوز حجم التداول اليومي لها 35 مليار دولار أمريكي. كما تقدم المجموعة، التي تشتهر بحلول التداول المبتكرة، والامتثال الراسخ للوائح التنظيمية، وخدمة العملاء الاستثنائية، مجموعة من خدمات الوساطة وحلول إدارة الأصول، ثم إنها تخضع للوائح التنظيمية في خمس قارات والتي تطبقها أكثر من 18 من أبرز السلطات المالية المرموقة عالميًا. هذا، وتقدم منصات التداول الحائزة على جوائز التابعة للمجموعة رافعة مالية بنسبة 1000:1 على مجموعة متنوعة من المنتجات، بما في ذلك الفوركس والمعادن والأسهم والسلع والمؤشرات والعملات المشفرة. وأخيرًا وليس آخرًا، حصلت MultiBank Group على أكثر من 80 جائزة تقديرًا لها على إسهاماتها في المجال المالي والتزامها بالتميز في مجال التداول وامتثالها للوائح التنظيمية. لمزيد من المعلومات، الرجاء زيارة موقع MultiBank Group الإلكتروني على www.multibankgroup.com.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260831401493/en

الرابط الثابت
https://www.aetoswire.com/ar/news/0109202656986

جهات الاتصال

 Nikolas Neofytou
 nikolas.neofytou@multibankfx.com

MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments

DUBAI, United Arab Emirates - Monday, 31. August 2026 

• David Ogg appointed Vice Chairman and Brian Andreyko named CEO

 

(BUSINESS WIRE)--MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform.

David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also included senior roles at Credit Suisse, Lehman Brothers, HSBC and Dresdner Kleinwort Benson, as well as work with Bloomberg and Citibank on institutional FX trading solutions. He has been inducted into the Profit & Loss Hall of Fame.

Commenting on his appointment, David Ogg, Vice Chairman of MEX Exchange, said: “Institutional FX has evolved considerably over the past several decades, but there remains significant scope for innovation in how liquidity is accessed, matched and executed. At MEX Exchange, our focus is on combining deep market expertise with advanced technology to build an institutional trading venue that addresses the evolving requirements of market participants globally. I look forward to supporting the company’s strategic direction in my new role as Vice Chairman.”

Brian Andreyko brings over 30 years of experience in financial technology and institutional markets, with a track record of building, scaling and leading electronic trading businesses. He previously served as Chief Operating Officer and Chief of Staff at Currenex, and as Executive Vice President and Head of EBS at ICAP. He also served as CEO of MakoFX/Liquidity Pool and Chief Business Officer at TradAir, both of which were subsequently acquired.

Brian Andreyko, CEO of MEX Exchange, said: “MEX Exchange has a clear opportunity to bring a differentiated proposition to the institutional trading market. My priority as CEO will be to translate our technology and market expertise into a scalable platform that delivers speed, efficiency and a strong execution experience bringing together Emerging Market and Global participants. I look forward to working closely with David and the wider team as we move into the next stage of the company’s growth.”

The appointments form part of MEX Exchange’s continued investment in its leadership and institutional capabilities, supporting its ambition to expand its presence across global electronic trading markets.

ABOUT MULTIBANK GROUP

MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives, serving over 2 million clients across 100 countries, and boasts a daily trading volume that exceeds $35 billion. Renowned for its innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group offers an array of brokerage services and asset management solutions. It is regulated across five continents by 18+ of the most reputable financial authorities globally. The group’s award-winning trading platforms offer up to 1000:1 leverage on a diverse range of products, including Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 financial awards recognizing its trading excellence and regulatory compliance. For more information, visit MultiBank Group’s www.multibankgroup.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831401493/en/

Permalink
https://www.aetoswire.com/en/news/3108202656968

Contacts

Nikolas Neofytou
nikolas.neofytou@multibankfx.com

BeOne Medicines تعلن حصول نظام علاجي قائم على TEVIMBRA على موافقة إدارة الغذاء والدواء الأمريكية لعلاج الخط الأول من سرطان المعدة والمريء الغدي المتقدم أو النقيلي الإيجابي لمستقبلات HER2+ GEA

 سان كارلوس، كاليفورنيا -

 يُعدّ TEVIMBRA وZIIHERA والعلاج الكيميائي أول نظام علاجي قائم على العلاج المناعي، والوحيد من نوعه حتى الآن، الذي حقق متوسط بقاء إجمالي يتجاوز عامين لدى المرضى المصابين بسرطان المعدة والمريء الغدي المتقدم أو النقيلي الإيجابي لمستقبلات HER2+ GEA في خط العلاج الأول، وذلك بغض النظر عن حالة PD-L1

 نظام علاجي يُتوقع أن يصبح معيار الرعاية المعتمد لعلاج هذا المرض الذي يصعب علاجه.

(BUSINESS WIRE)-- أعلنت BeOne Medicines Ltd. (المدرجة في بورصة ناسداك بالرمز: ONC؛ وبورصة هونج كونج: 06160؛ وبورصة شنغهاي: 688235)، إحدى الشركات العالمية المتخصصة في علم الأورام، اليوم أن إدارة الغذاء والدواء الأمريكية (FDA) وافقت على طلب ترخيص بيولوجي تكميلي (sBLA) لاستخدام TEVIMBRA® (tislelizumab) بالاشتراك مع ZIIHERA® (zanidatamab) والعلاج الكيميائي، كعلاج من الخط الأول للمرضى البالغين المصابين بسرطان غدي إيجابي لمستقبل HER2 (HER2+) في المعدة أو الوصلة المعدية المريئية أو المريء (GEA)، في الحالات المتقدمة موضعيًا وغير القابلة للاستئصال أو الحالات النقيلية. تستند هذه الموافقة إلى نتائج دراسة HERIZON-GEA-01 من المرحلة الثالثة، التي نُشرت في وقت سابق من هذا العام في مجلة The New England Journal of Medicine.

 يشمل السرطان الغدي المعدي المعوي (GEA) أورامًا غدية تصيب المعدة والوصلة المعدية المريئية والمريء، ولا يزال يمثل مجالاً تبرز فيه حاجة طبية كبيرة غير ملباة في الولايات المتحدة، حيث يُشخَّص أكثر من 31,000 حالة جديدة من سرطان المعدة سنويًا.1 ويعاني نحو 20% من مرضى GEA من أورام إيجابية لمستقبلات HER2+، وهي فئة فرعية لطالما شكّلت تحديًا علاجيًا كبيرًا.2,3,4

على الرغم من التطورات التي تحققت مؤخرًا، لا تزال النتائج العلاجية طويلة الأمد للمرضى المصابين بالسرطان الغدي المعدي المعوي (GEA) الإيجابي لمستقبلات HER2+ المتقدم أو النقيلي تمثل تحديًا كبيرًا، فيما تبرز حاجة ملحّة إلى خيارات علاجية أكثر فعالية من الخط الأول. في الولايات المتحدة، لا تتجاوز نسبة المرضى الذين يظلون على قيد الحياة لأكثر من عامين 40%. وتسلّط هذه النتائج الضوء على الحاجة إلى خيارات علاجية إضافية قد تسهم في إطالة بقاء المرضى على قيد الحياة في مواجهة هذا المرض.

 قال Jaffer A. Ajani، دكتوراه في الطب (.M.D)، أستاذ علم الأورام الطبي للجهاز الهضمي في MD Anderson Cancer Center التابع لجامعة تكساس:

"بالنسبة إلى المرضى المصابين بالسرطان الغدي المتقدم في المعدة أو الوصلة المعدية المريئية، والإيجابي لمستقبلات HER2، يمثل علاج الخط الأول فرصة حاسمة لإحداث أكبر تأثير ممكن وتغيير مسار المرض منذ بداية العلاج. ومن ثمَّ، تكتسب إتاحة أكثر الخيارات والتركيبات العلاجية فعالية منذ البداية أهمية خاصة، بما يمنح المرضى أفضل فرصة ممكنة لتحقيق نتائج محسّنة. ويمثل تحقيق متوسط بقاء إجمالي يتجاوز عامين باستخدام هذا النظام العلاجي تقدمًا مهمًا وملموسًا في مجال ظل تحسين النتائج العلاجية فيه يمثل تحديًا تاريخيًا. ومع ثبوت الفائدة العلاجية لدى مختلف الفئات بحسب حالة PD-L1، تتيح هذه الموافقة للأطباء قدرًا أكبر من المرونة في اختيار النظام العلاجي الأنسب، دون أن تكون حالة PD-L1 عاملاً محددًا لاختيار العلاج".

 قال Mark Lanasa، الدكتور والحاصل على دكتوراه في الفلسفة، والرئيس الطبي لقطاع الأورام الصلبة في BeOne Medicines:

"تمثل موافقة اليوم محطة مهمة في مسيرة BeOne، بينما نواصل توسيع نطاق الاستفادة من TEVIMBRA وإحداث تأثير أكبر في حياة المرضى المصابين بالسرطان. "وبصفته أول علاج محوري معتمد ينبثق من محفظتنا لعلاج الأورام الصلبة، أثبت TEVIMBRA إمكاناته في تلبية احتياجات طبية كبيرة غير ملباة عبر مجموعة متنوعة من أنواع الأورام. وتعكس موافقة اليوم التزامنا الراسخ بمواصلة تطوير تركيبات علاجية مبتكرة قائمة على TEVIMBRA وقادرة على إحداث تحول في الممارسة السريرية، بما يوفر خيارات علاجية جديدة للمرضى الذين يواجهون سرطانات يصعب علاجها. نفخر بإتاحة هذا الخيار العلاجي الجديد من الخط الأول أمام الأطباء والمرضى المصابين بالسرطان الغدي في المعدة أو الوصلة المعدية المريئية الإيجابي لمستقبلات HER2 في الولايات المتحدة".

 قالت Aki Smith، المؤسسة والمديرة التنفيذية لمنظمة Hope for Stomach Cancer:

"بالنسبة إلى المصابين بالسرطان الغدي في المعدة أو الوصلة المعدية المريئية الإيجابي لمستقبلات HER2 وعائلاتهم، قد يعني إتاحة مزيد من الوقت كل شيء؛ مزيدًا من اللحظات التي يقضونها مع أحبائهم، ومزيدًا من المناسبات والمحطات المهمة التي يعيشونها معًا، ومزيدًا من الأمل والثقة في إحراز تقدم حقيقي في مواجهة مرض لا تزال الحاجة إلى خيارات علاجية إضافية له ملحّة للغاية. بصفتي مقدمةً للرعاية لوالدي، الذي عانى من سرطان غدي في المعدة أو الوصلة المعدية المريئية إيجابي لمستقبل HER2، أعرف عن قرب مشاعر الخوف والقلق التي تنتاب العائلات مع بدء رحلة العلاج، وأدرك تمامًا مدى أهمية أن تتوافر خيارات علاجية إضافية منذ البداية. نسعد بإتاحة هذا النظام العلاجي الجديد، ونؤكد التزامنا بمساعدة المرضى ومقدّمي الرعاية على فهم خياراتهم العلاجية والوصول إلى الدعم الذي يحتاجون إليه طوال رحلة العلاج".

 جاءت الموافقة استنادًا إلى نتائج دراسة HERIZON-GEA-01 من المرحلة الثالثة.

تستند الموافقة إلى بيانات HERIZON-GEA-01، وهي دراسة سريرية عالمية من المرحلة الثالثة تُقيّم فعالية ZIIHERA بالاشتراك مع العلاج الكيميائي، مع TEVIMBRA أو من دونه، مقارنةً بـ trastuzumab بالاشتراك مع العلاج الكيميائي، كعلاج من الخط الأول للمرضى المصابين بالسرطان الغدي المتقدم أو النقيلي في المعدة أو الوصلة المعدية المريئية أو المريء (GEA)، الإيجابي لمستقبلات HER2+.

تشمل أبرز النتائج التي توصلت إليها التجربة ما يلي:

البقاء الكلي على قيد الحياة (OS): أظهر نظام TEVIMBRA بالاشتراك مع ZIIHERA والعلاج الكيميائي تحسنًا ذا دلالة إحصائية في البقاء الإجمالي، إذ بلغ متوسط البقاء الإجمالي 26.4 شهرًا مقابل 19.2 شهرًا في ذراع التحكم.

البقاء دون تقدم المرض (PFS): أظهر نظام TEVIMBRA بالاشتراك مع ZIIHERA والعلاج الكيميائي تحسنًا ذا دلالة إحصائية وملاءمة سريرية في البقاء دون تقدم المرض (PFS)، حيث بلغ متوسط البقاء دون تقدم المرض 12.4 شهرًا، مقارنةً بـ8.1 شهرًا في ذراع التحكم.

فائدة علاجية متسقة بغض النظر عن حالة PD-L1: أظهر نظام TEVIMBRA بالاشتراك مع ZIIHERA والعلاج الكيميائي تحسنًا في البقاء الإجمالي والبقاء دون تقدم المرض عبر مختلف فئات المرضى، بما في ذلك المصابين بأورام سلبية لـ PD-L1 (TAP <1%). وبلغ متوسط البقاء الإجمالي لدى هذه الفئة 29.7 شهرًا، مقابل 15.8 شهرًا في ذراع التحكم.

اتساق الفعالية العلاجية عبر مختلف مستويات التعبير عن HER2: أظهر نظام TEVIMBRA + ZIIHERA والعلاج الكيميائي فائدة علاجية لدى المرضى في كل من مجموعتي HER2 IHC (الكيمياء المناعية) 3+ وHER2 IHC 2+.

السلامة: أظهر العلاج باستخدام TEVIMBRA بالاشتراك مع ZIIHERA والعلاج الكيميائي اتساقًا بصورة عامة مع ملفات السلامة المعروفة لكل مكوّن من مكونات النظام العلاجي، ولم تُرصد أي إشارات جديدة تتعلق بالسلامة.

 نبذة عن دراسة HERIZON-GEA-01 - المرحلة الثالثة:

 تُعد دراسة HERIZON-GEA-01 ( NCT05152147 ) تجربة عالمية عشوائية مفتوحة التسمية من المرحلة الثالثة، أُجريت بالتعاون مع Jazz Pharmaceuticals، بهدف تقييم ومقارنة فعالية وسلامة نظام ZIIHERA مع العلاج الكيميائي، مع أو بدون TEVIMBRA، مقابل معيار الرعاية القياسي المتمثل في trastuzumab مع العلاج الكيميائي، وذلك كعلاج من الخط الأول للمرضى البالغين المصابين بسرطان المعدة والمريء الغدي المتقدم أو النقيلي الإيجابي لمستقبلات HER2+ GEA. شملت الدراسة توزيعًا عشوائيًا لـ 914 مريضًا عبر ما يقارب 300 موقعًا بحثيًا في أكثر من 30 دولة حول العالم. كان المرضى المشاركون في هذه التجربة يعانون من سرطان المعدة أو المريء HER2+ غير القابل للاستئصال موضعيًا أو المتكرر أو النقيلي، والذي تم تعريفه على أنه تعبير HER2 بدرجة 3+ وفق فحص المناعة النسيجية (IHC)، أو تعبير HER2 بدرجة 2+ مع نتيجة إيجابية لفحص التهجين الموضعي (ISH). تم توزيع المرضى عشوائيًا على ثلاثة أذرع تجريبية: ZIIHERA مع العلاج الكيميائي وTEVIMBRA؛ وZIIHERA مع العلاج الكيميائي فقط؛ وtrastuzumab مع العلاج الكيميائي. تقوم الدراسة بتقييم نقطتين أساسيتين مزدوجتين، البقاء دون تقدم المرض (PFS) وفقًا للمراجعة المركزية المستقلة المزدوجة التعمية (BICR)، والبقاء الكلي على قيد الحياة (OS).

 نبذة عن ZIIHERA (zanidatamab-hrii)

 يُعدّ دواء ZIIHERA (zanidatamab) جسمًا مضادًا ثنائي النوعية موجهًا ضد مستقبل عامل نمو البشرة البشري 2 (HER2)، حيث يرتبط بموقعين خارج خلويين على HER2. ويؤدي ارتباط zanidatamab بـ HER2 إلى عملية إدخال داخل الخلية، مما يساهم في تقليل مستوى تعبير مستقبل HER2 على سطح الخلية السرطانية. يحفّز Zanidatamab عدة آليات مناعية مضادة للورم، تشمل السُمّية الخلوية المعتمدة على المتممة (CDC)، والسُمّية الخلوية المعتمدة على الأجسام المضادة (ADCC)، والبلعمة الخلوية المعتمدة على الأجسام المضادة (ADCP). تؤدي هذه الآليات إلى تثبيط نمو الورم وتحفيز موت الخلايا السرطانية في الدراسات المخبرية والدراسات الحية.5

يتم تطوير دواء Zanidatamab ضمن عدة تجارب سريرية كخيار علاجي موجّه للمرضى المصابين بأورام صلبة تُعبّر عن مستقبل HER2. تمت الموافقة على استخدام دواء Zanidatamab في الصين لعلاج المرضى المصابين بسرطان القنوات الصفراوية (BTC) غير القابل للاستئصال، أو المتقدم موضعيًا، أو النقيلي، والذين يُظهرون تعبيرًا مرتفعًا عن HER2 (IHC 3+) وقد تلقّوا علاجًا نظاميًا سابقًا. حصل دواء ZIIHERA أيضًا على موافقة مُعجَّلة في الولايات المتحدة، وعلى ترخيص تسويق مشروط في الاتحاد الأوروبي، وذلك لعلاج المرضى المؤهَّلين المصابين بسرطان القنوات الصفراوية (BTC). يتم تطوير دواء Zanidatamab من قِبل شركتي Jazz وBeOne بموجب اتفاقيات ترخيص مع شركة Zymeworks، التي قامت بتطوير الجزيء لأول مرة. وقد حصلت BeOne على ترخيص استخدام zanidatamab من Zymeworks في آسيا (باستثناء الهند واليابان)، إضافة إلى أستراليا ونيوزيلندا، بينما تمتلك شركة Jazz Pharmaceuticals حقوق تطويره وتسويقه في جميع المناطق الأخرى.

ZIIHERA هي علامة تجارية مسجلة لشركة Zymeworks BC Inc.

 نبذة عن TEVIMBRA (tislelizumab-jsgr)

يُعدّ دواء TEVIMBRA جسمًا مضادًا وحيد النسيلة من نوع الغلوبولين المناعي البشري G4 (IgG4)، وموجّهًا ضد بروتين موت الخلايا المبرمج 1 (PD-1). يتميز هذا الدواء بتصميم فريد وبألفة عالية وانتقائية ارتباط دقيقة بمستقبل PD-1. تم تصميمه لتقليل الارتباط بمستقبلات Fc-gamma (Fcγ) الموجودة على الخلايا البلعمية، مما يساعد على تعزيز قدرة الخلايا المناعية في الجسم على التعرف على الأورام ومكافحتها بشكل أكثر فعالية.

يُعدّ TEVIMBRA أحد الأصول الأساسية لمحفظة الأورام الصلبة الخاصة بشركة BeOne وقد أظهر إمكانات عبر أنواع متعددة من الأورام وإعدادات المرض. يتضمن برنامج التطوير السريري العالمي لـ TEVIMBRA ما يقرب من 15,000 مريض مسجلين حتى الآن في أكثر من 30 مقاطعة ومنطقة عبر 71 تجربة، بما في ذلك 21 دراسة تمكينية للتسجيل. تمت الموافقة على TEVIMBRA في أكثر من 50 سوقًا، وتم علاج أكثر من 2 مليون مريض على مستوى العالم.

 المعلومات المهمة المختارة للسلامة

حدثت تفاعلات عكسية خطيرة، وأحيانًا مميتة، مع العلاج بدواء TEVIMBRA. تشمل التحذيرات والاحتياطات حدوث تفاعلات ضارة شديدة، وقد تكون مميتة، ناجمة عن تنشيط الجهاز المناعي، بما في ذلك التهاب الرئة، والتهاب القولون، والتهاب الكبد، واضطرابات الغدد الصماء، والتهاب الكلى المصحوب بخلل في وظائف الكلى، والتفاعلات الجلدية الضارة، ورفض زراعة الأعضاء الصلبة. كما تشمل التحذيرات الأخرى تفاعلات مرتبطة بالتسريب الوريدي، ومضاعفات زراعة الخلايا الجذعية المكوِّنة للدم من متبرع (HSCT)، إضافة إلى السُمّية على الجنين أثناء الحمل.

كانت أكثر التفاعلات الضارة شيوعًا (بنسبة ≥20%)، بما في ذلك الاختلالات في نتائج الفحوصات المخبرية، لدى المرضى الذين تلقوا TEVIMBRA + zanidatamab + العلاج الكيميائي، هي: الإسهال، والغثيان، وفقر الدم، وانخفاض الشهية، والقيء، وانخفاض عدد العدلات، ونقص بوتاسيوم الدم، والإرهاق، والطفح الجلدي، وانخفاض عدد الصفائح الدموية، والاعتلال العصبي المحيطي، والتفاعل المرتبط بالتسريب، وارتفاع مستوى إنزيم ناقلة الأسبارتات.

 يُرجى الاطّلاع على نشرة المعلومات الدوائية الكاملة المعتمدة في الولايات المتحدة بما في ذلك دليل الأدوية في الولايات المتحدة .

 المعلومات الواردة في هذا البيان الصحفي موجهة للجمهور حول العالم. وقد تختلف دواعي استخدام المنتجات من منطقة إلى أخرى.

 نبذة عن BeOne

 تعدّ شركة BeOne Medicines شركة عالمية في مجال الأورام، تعمل على اكتشاف وتطوير علاجات مبتكرة لمرضى السرطان حول العالم. ومن خلال محفظة أعمال تشمل أمراض الدم والأورام الصلبة، تعمل BeOne على تسريع تطوير خطها المتنوع من العلاجات الجديدة عبر قدراتها الداخلية وشراكاتها التعاونية. تمتلك الشركة فريقًا عالميًا متناميًا يغطي ست قارات، ويتميز بالدافع نحو التميز العلمي والسرعة الاستثنائية للوصول إلى عدد أكبر من المرضى أكثر من أي وقت مضى. لمعرفة المزيد عن BeOne، تفضَّل بزيارة www.beonemedicines.com وتابعنا على LinkedIn، وX، وFacebook، وInstagram.

 البيان التطلعي

 يتضمن هذا البيان الصحفي بيانات تطلعية بالمعنى المقصود في قانون إصلاح التقاضي الخاص بالأوراق المالية لعام 1995 وغيره من قوانين الأوراق المالية الفيدرالية، بما في ذلك ما يتعلق بإمكانات TEVIMBRA في تلبية احتياجات طبية كبيرة غير ملباة عبر مختلف أنواع الأورام؛ والتزام BeOne بمواصلة تطوير الأنظمة العلاجية المركبة التي تتضمن TEVIMBRA؛ وإمكان أن يصبح الجمع بين TEVIMBRA وZIIHERA والعلاج الكيميائي معيارًا جديدًا للرعاية في علاج السرطان الغدي المعدي المعوي الإيجابي لمستقبلات HER2+؛ والبيانات المتعلقة بالفوائد المحتملة لكل من TEVIMBRA وZIIHERA؛ إضافةً إلى خطط BeOne والتزاماتها وتطلعاتها وأهدافها الواردة تحت عنوان "نبذة عن BeOne". قد تختلف النتائج الفعلية ماديًا عن تلك المُشار إليها في البيانات التطلعية نتيجة لعوامل مهمة مختلفة، بما في ذلك قدرة BeOne على إثبات مدى فعالية وسلامة الأدوية المرشحة لها؛ النتائج السريرية للأدوية المرشحة، والتي قد لا تدعم المزيد من التطوير أو الموافقة على التسويق؛ إجراءات الهيئات التنظيمية، والتي قد تؤثر في بدء وتوقيت وتقدُّم التجارب السريرية والموافقة على التسويق؛ قدرة BeOne على تحقيق النجاح التجاري للأدوية المسوقة والأدوية المرشحة، في حالة الموافقة عليها؛ قدرة BeOne على الخضوع للحماية بموجب حقوق الملكية الفكرية لأدويتها وتقنياتها والحفاظ عليها؛ اعتماد BeOne على أطراف ثالثة لإجراء تطوير الأدوية وتصنيعها وتسويقها وخدمات أخرى؛ خبرة BeOne المحدودة في الحصول على الموافقات التنظيمية وتسويق المنتجات الصيدلانية؛ وقدرتها على الحصول على تمويل إضافي للعمليات واستكمال تطوير الأدوية المرشحة لها وتحقيق الربحية والحفاظ عليها؛ وتمت مناقشة هذه المخاطر بشكل أكثر تفصيلاً في القسم المعنون "عوامل الخطر" في أحدث تقرير ربع سنوي لشركة BeOne بشأن النموذج 10-Q، إضافة إلى مناقشات المخاطر المحتملة والشكوك والعوامل المهمة الأخرى في ملفات BeOne اللاحقة لدى لجنة الأوراق المالية والبورصات الأمريكية. جميع المعلومات الواردة في هذا البيان الصحفي تسري ابتداءً من تاريخ هذا البيان الصحفي، ولا تتحمَّل BeOne أي واجب أو التزام لتحديث هذه المعلومات ما لم يكن ذلك مطلوبًا بموجب القانون.

 للاطّلاع على موارد BeOne الإعلامية، يُرجى زيارة موقع غرفة الأخبار لدينا.

1 American Cancer Society. Key Statistics About Stomach Cancer. American Cancer Society. Updated: February 27, 2026. https://www.cancer.org/cancer/types/stomach-cancer/key-statistics.html

2 Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22(19):4619–4625.

3 Van Cutsem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484

4 Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. Cancer Treat Rev. 2021;99:102249.

5 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).

 إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

الرابط الثابت

https://www.aetoswire.com/ar/news/2608202656900

جهات الاتصال

 جهة اتصال المستثمر

 Liza Heapes

 1 8573025663

 ir@beonemed.com

 جهة اتصال الإعلام

 Kyle Blankenship

 1 6673515176

 media@beonemed.com

تحديث المختبرات يعزِّز التزام شركة QPS Holdings, LLC طويل الأمد بالتحليل الحيوي للعناصر

 غرونينغن، هولندا 

(BUSINESS WIRE)-- أعلنت شركة QPS Holdings, LLC (QPS) اليوم عن تنفيذ عملية تحديث كبيرة للبنية التحتية الخاصة بخدمات التحليل الحيوي للعناصر، وذلك من خلال اقتناء جهازين من طراز PerkinElmer NexION® 2200 لتحليل العناصر باستخدام أنظمة مطيافية الكتلة بالبلازما المقترنة حثيًا (ICP-MS)، على أن يتم تشغيل الجهازين في مختبرات الشركة في هولندا. وستحل الأجهزة الجديدة محل نظامين من طراز Agilent 7700 ICP-MS يعملان حاليًا ضمن قسم التحليل الحيوي. وقد وقع الاختيار على منصة NexION® 2200 لما توفره من إمكانات متقدمة لإجراء تحاليل موثوقة للعناصر النزرة، والإدارة الفعّالة للتداخلات التحليلية، وتحقيق أداء موثوق عند التعامل مع عينات ذات مصفوفات معقدة، إلى جانب تعزيز كفاءة العمليات المخبرية.

ويأتي هذا الاستثمار في إطار برنامج أوسع لتحديث مرافق الشركة وتجديدها، حيث يركز على الحفاظ على قدرات متطورة وموثوقة ومستدامة في مجال مطيافية الكتلة عبر مختبرات QPS المنتشرة حول العالم. وإضافةً إلى استبدال المعدات التحليلية الحالية، يشمل هذا التحديث تأهيل الأجهزة، ونقل الطرق التحليلية، وتحسين سير العمل، وتدريب الموظفين، وإدارة دورة حياة الأجهزة على المدى الطويل.

وستعمل QPS ممثلةً في فرعها في هولندا على إدخال الأجهزة الجديدة من خلال عملية تنفيذ وتأهيل محكمة ومنضبطة، بما يضمن جاهزيتها للتشغيل وفقًا للمعايير والمتطلبات المعتمدة. وستُقيّم الطرق التحليلية الحالية ويتم نقلها باستخدام إجراءات مناسبة لإثبات قابلية المقارنة أو الربط أو التحقق من الصحة، وذلك وفقًا للاستخدام المقصود لكل طريقة ووضعها التنظيمي. ويهدف هذا النهج إلى ضمان استمرارية الدراسات الجارية، مع توفير منصة مُحدّثة تدعم تطوير الطرق التحليلية والتحقق من صحتها في المستقبل.

وقال Fred van Heuveln، مدير قسم التحليل الحيوي في QPS: "تُعد تقنية مطيافية الكتلة بالبلازما المقترنة حثيًا (ICP-MS) جزءًا مهمًا من خدماتنا في مجال التحليل الحيوي، لا سيما في البرامج التي تتطلب قياسًا كميًا عالي الحساسية والانتقائية للعناصر في المصفوفات البيولوجية المعقدة". "ومن خلال استبدال النظامين في الوقت نفسه، نعمل على إنشاء منصة تحليلية مُحدّثة تضمن تنفيذ المشاريع بكفاءة وموثوقية، من خلال تطبيق الطرق التحليلية وتحليل العينات بكفاءة، مع توفير منصة قادرة على مواكبة المتطلبات المتطورة لعملائنا".

وسيوفر تهيئة النظامين معًا مرونة تشغيلية وقدرة تكرار إضافية. ومن المتوقع أن يسهم توحيد منصة أجهزة ICP-MS في تبسيط عمليات التدريب والصيانة ونقل الطرق التحليلية والدعم المخبري الروتيني، إلى جانب مساعدة QPS على إدارة الجداول الزمنية للدراسات بكفاءة والتكيف مع المتطلبات التحليلية المتغيرة.

وأضاف Daniel Schulz-Jander، المدير الأول لقسم التحليل الحيوي في QPS: "تمثل هذه المبادرة أكثر من مجرد استبدال للمعدات". "يضمن هذا التحديث الاستراتيجي لأنظمة ICP-MS حفاظ QPS على أحدث التقنيات المتطورة، بما يمكّننا من تقديم حلول تحليلية عالية الحساسية والموثوقية وراسخة، تلبي متطلبات مشاريع عملائنا. ويعزز هذا الاستثمار التزامنا المتواصل بتقديم خدمات استثنائية في مجال التحليل الحيوي للعناصر، بما يدعم برامج تطوير الأدوية التقليدية والناشئة على حد سواء".

 تمتلك QPS ممثلة في فرعها في هولندا خبرة تمتد لأكثر من عقدين في مجال التحليل الحيوي القائم على تقنية مطيافية الكتلة بالبلازما المقترنة حثيًا (ICP-MS). وتشمل قدراتها التحليل الكلي للعناصر، وتحليل العناصر الحرة والعناصر النزرة، بالإضافة إلى تطبيقات LC-ICP-MS في تحديد الأنواع الكيميائية للعناصر، ودراسات الثبات، والأبحاث المتعلقة بالمستقلبات. وتتواصل حاليًا أعمال تركيب وتأهيل وتنفيذ التشغيل المرحلي لنظامي NexION® 2200، ومن المقرر استكمالها خلال الربع الثالث من عام 2026.

 نبذة عن شركة QPS HOLDINGS, LLC

 QPS هي منظمة بحثية تعاقدية عالمية متكاملة الخدمات متوافقة مع الممارسات المختبرية الجيدة/الممارسات السريرية الجيدة تقدم أعلى مستوى من خدمات الاكتشاف والتحليل الحيوي وتطوير الأدوية السريرية وما قبل السريرية. ومنذ عام 1995، تطورت شركة QPS من متجر صغير للتحليل الحيوي إلى منظمة بحثية تعاقدية تقدم خدمات كاملة تضم أكثر من 1200 موظف في الولايات المتحدة وأوروبا وآسيا. تقدم QPS اليوم مجموعة موسّعة من خدمات البحث والتطوير التعاقدية في قطاع الصناعات الدوائية، مستندةً إلى خبرات متخصصة في مجالات علم الأدوية، وديناميكا الدواء وحركية الدواء (DMPK)، وعلم السموم، والتحليل الحيوي، والطب الانتقالي، ووحدات التجارب السريرية، وخدمات المختبرات المركزية، ومعالجة الخلايا أحادية النواة في الدم المحيطي (PBMC)، وخدمات عمليات البحوث السريرية. تُعدَّ شركة QPS شركة رائدة حائزة على جوائز في مجال التحليل البيولوجي والتجارب السريرية، وهي معروفة باتباع معايير الجودة المثبتة والخبرة الفنية والنهج المرن في البحث ورضا العملاء والمختبرات والمرافق الجاهزة. ومن خلال التحسينات المستمرة في القدرات والموارد، تظل شركة QPS متمسكة بالتزامها بتقديم جودة متفوقة وأداء فائق وخدمة موثوقة لعملائها الكرام. لمزيد من المعلومات، تفضّل بزيارة www.qps.com، أو راسلنا عبر البريد الإلكتروني info@qps.com، أو تابعنا على LinkedIn.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260831322534/en

الرابط الثابت

https://www.aetoswire.com/ar/news/0109202656978

جهات الاتصال

 QPS:

 الاسم: Gabrielle Pastore

 الهاتف: 1-302-635-4290

 البريد الإلكتروني: Gabrielle.Pastore@QPS.com

Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis

 GRONINGEN, Netherlands - 

(BUSINESS WIRE)--QPS Holdings, LLC (QPS) today announced a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 inductively coupled plasma mass spectrometry (ICP-MS) systems to be housed in its Netherlands laboratories. The new instruments will replace two Agilent 7700 ICP-MS systems currently operating within the bioanalysis department. The NexION® 2200 platform was selected to support robust trace-element analysis, effective management of analytical interferences, reliable performance with challenging sample matrices, and efficient laboratory operations.

The investment is part of a broader upgrade and renewal program focused on maintaining a modern, reliable, and sustainable mass spectrometry capabilities across QPS global laboratory facilities. In addition to replacing established analytical equipment, the upgrade encompasses instrument qualification, method transfer, workflow optimization, employee training, and long-term lifecycle management.

QPS Netherlands will introduce the new instruments through a controlled implementation and qualification process. Existing methods will be assessed and transferred using appropriate comparability, bridging, or validation activities, depending on their intended use and regulatory status. This approach is designed to maintain continuity for ongoing studies while establishing a renewed platform for future method development and validation.

“ICP-MS is an important part of our bioanalytical offering, particularly for programs requiring sensitive and selective quantification of elements in complex biological matrices,” said Fred van Heuveln, QPS Director, Bioanalysis. “By replacing both systems at the same time, we are creating an upgraded analytical platform that will ensure reliable project execution through efficient method deployment and sample analysis, while providing a platform for the evolving requirements of our clients.”

The two-system configuration will provide operational flexibility and redundancy. Standardizing the ICP-MS platform is expected to simplify training, maintenance, method transfer and routine laboratory support while helping QPS manage study schedules and changing analytical demands.

“This initiative represents more than an equipment replacement,” added Daniel Schulz-Jander, QPS Senior Director, Bioanalysis. “This strategic renewal of our ICP-MS systems ensures QPS maintains cutting-edge technology to deliver highly sensitive and robust analytical solutions for our clients' projects. This investment reinforces our ongoing commitment to providing exceptional elemental bioanalysis for both traditional and emerging drug development programs.”

QPS Netherlands has more than two decades of experience with ICP-MS-based bioanalysis. Its capabilities include total, free and trace elemental analysis, as well as LC-ICP-MS applications for speciation, stability and metabolite-related investigations. Installation, qualification, and phased implementation of the two NexION® 2200 systems are ongoing and scheduled to be completed in Q3 2026.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trial units, central laboratory services, PBMC processing, and clinical research operations services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com, email info@qps.com, or follow us on LinkedIn.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831322534/en/

Permalink

https://www.aetoswire.com/en/news/3108202656966

Contacts

QPS:

Name: Gabrielle Pastore

Phone: 1-302-635-4290

Email: Gabrielle.Pastore@QPS.com

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

 (BUSINESS WIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC).

The continuing research seeks to evaluate the efficacy and safety of L-glutamine in patients battling pancreatic cancer, an area of significant unmet medical need. This option agreement follows the results of the GlutaPanc trial (NCT04634539), recently published in Nature Cancer.

"We are incredibly proud to explore the broader potential of our therapies," said Willis Lee, Chairman and Chief Executive Officer of Emmaus Life Sciences. "While Emmaus has historically been recognized for our breakthrough treatment in sickle cell disease, we believe that this agreement represents an important step in exploring new options for patients with pancreatic cancer.”

PDAC is the most common type of pancreatic cancer and is notoriously difficult to treat, often presenting with late-stage diagnoses and limited therapeutic options. The collaboration with Cedars-Sinai researchers leverages the institution's premier oncological research capabilities alongside Emmaus' expertise in drug development for orphan diseases.

The safety and efficacy of L-glutamine for the treatment of PDAC have not been established. There is no guarantee that L-glutamine will receive regulatory approval for this investigational use.

About Emmaus Life Sciences Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Kuwait, Qatar, the United Arab Emirates, Bahrain, Oman, and is available on a named-patient early access program in other countries. For more information, please visit www.emmausmedical.com.

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, regarding the potential efficacy of L-glutamine for the treatment of pancreatic cancer and the expected publication of Phase 1 study results. These forward-looking statements are subject to numerous assumptions, risks, and uncertainties that change over time, including the risks and other factors previously disclosed in the company's reports filed with the Securities and Exchange Commission, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831760299/en/

Permalink

https://aetoswire.com/en/news/3108202656967

Contacts

Company Contact:

Emmaus Life Sciences, Inc.

Public Relations

(310) 214-0065

PR@emmauslifesciences.com

 (BUSINESS WIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC).

The continuing research seeks to evaluate the efficacy and safety of L-glutamine in patients battling pancreatic cancer, an area of significant unmet medical need. This option agreement follows the results of the GlutaPanc trial (NCT04634539), recently published in Nature Cancer.

"We are incredibly proud to explore the broader potential of our therapies," said Willis Lee, Chairman and Chief Executive Officer of Emmaus Life Sciences. "While Emmaus has historically been recognized for our breakthrough treatment in sickle cell disease, we believe that this agreement represents an important step in exploring new options for patients with pancreatic cancer.”

PDAC is the most common type of pancreatic cancer and is notoriously difficult to treat, often presenting with late-stage diagnoses and limited therapeutic options. The collaboration with Cedars-Sinai researchers leverages the institution's premier oncological research capabilities alongside Emmaus' expertise in drug development for orphan diseases.

The safety and efficacy of L-glutamine for the treatment of PDAC have not been established. There is no guarantee that L-glutamine will receive regulatory approval for this investigational use.

About Emmaus Life Sciences Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Kuwait, Qatar, the United Arab Emirates, Bahrain, Oman, and is available on a named-patient early access program in other countries. For more information, please visit www.emmausmedical.com.

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, regarding the potential efficacy of L-glutamine for the treatment of pancreatic cancer and the expected publication of Phase 1 study results. These forward-looking statements are subject to numerous assumptions, risks, and uncertainties that change over time, including the risks and other factors previously disclosed in the company's reports filed with the Securities and Exchange Commission, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831760299/en/

Permalink

https://aetoswire.com/en/news/3108202656967

Contacts

Company Contact:

Emmaus Life Sciences, Inc.

Public Relations

(310) 214-0065

PR@emmauslifesciences.com

 

Dhruva to Rebrand as Ryan Across the Middle East, Signaling Unified Global Brand

  

Dhruva will adopt the Ryan brand across the UAE and Saudi Arabia by the end of 2026, uniting the practice with Ryan’s global identity and international platform

 

(BUSINESS WIRE)--Dhruva, a leading tax consultancy firm in the Middle East, and Ryan, a leading global tax services and software provider, today announced that Dhruva will transition to the Ryan brand across the United Arab Emirates (UAE) and the Kingdom of Saudi Arabia. The rebranding will be completed by the end of 2026, bringing the practice under Ryan’s global identity and reinforcing its position as part of the world’s leading global-scale specialist in business tax.

The transition marks the next phase of the strategic joint venture announced in 2025 and reflects the continued integration of Dhruva’s regional capabilities with Ryan’s global platform, technology, and international resources. Clients across the Middle East will continue to benefit from the same trusted advisory teams, enhanced by access to Ryan’s worldwide expertise and service capabilities.

“The Middle East has been a strategic growth market for us for many years, and we have built a strong advisory practice founded on deep client relationships, technical excellence, and local market understanding,” said Dinesh Kanabar, Founder, Chairman, and CEO, Dhruva Advisors and Vice Chairman, Ryan. “The transition to the Ryan brand marks a significant milestone in our journey and reflects the strength of our partnership. By combining our regional expertise with Ryan’s global scale, technology, and international capabilities, we are creating an even stronger platform to support clients across the region as they navigate an increasingly dynamic and evolving tax landscape.”

“The Middle East is one of the most important growth markets for tax advisory services globally, and we are investing in the region with a long-term view,” said Tom Shave, President of Ryan's European and Asia-Pacific Operations. “Uniting under the Ryan brand strengthens how we serve clients across the UAE, Saudi Arabia, and Europe—bringing seamless access to our global expertise, technology, and international resources through one trusted platform. This transition marks an important milestone in our integration and reinforces our commitment to the region’s future.”

Ryan will continue to invest in its Middle East operations, expanding its team, capabilities, and regional presence across key markets, including Dubai, Abu Dhabi, and Riyadh. The practice provides comprehensive tax advisory services spanning corporate tax, value-added tax (VAT) and indirect tax, transfer pricing, mergers and acquisitions (M&A) tax structuring, research and development (R&D), and cross-border compliance.

“The response from our clients over the past year has been the clearest validation of this partnership,” said Nimish Goel, Leader, Middle East, Dhruva, a Ryan Affiliate. “From the outset, our teams have been integrating Ryan’s global capabilities in technology, specialized expertise, and best practices into the work we already lead in the region. Adopting the Ryan brand is the natural next step. It is the same people and the same trusted relationships, now carrying the name of the largest Firm in the world dedicated exclusively to business taxes.”

The rebranding will be implemented in phases during the second half of 2026, with signage, visual identity, and digital properties transitioning to the Ryan brand across the region.

About Ryan

Ryan, an award-winning global tax services and software provider, is the largest Firm in the world dedicated exclusively to business taxes. With global headquarters in Plano, Texas, the Firm provides an integrated suite of federal, state, local, and international tax services on a multijurisdictional basis, including tax recovery, consulting, advocacy, compliance, and technology services. Empowered by the dynamic myRyan work environment, which is widely recognized as the most innovative in the tax services industry, Ryan’s multidisciplinary team of more than 7,100 professionals and associates serves over 74,000 clients in more than 80 countries, including many of the world’s most prominent Global 5000 companies. More information about Ryan can be found at ryan.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831057145/en/

Permalink

https://www.aetoswire.com/en/news/31082002656969

Contacts

Media Contact

Allie Bandemer

Senior Specialist, Public Relations and External Communications

Ryan

331.251.1050

allie.bandemer@ryan.com

Rimini Street Announces Stock Repurchase and Debt Reduction Transactions

 LAS VEGAS - Monday, 31. August 2026 AETOSWire Print 

The Company recently completed an additional $5.0 million of common stock repurchases and $5.0 million of debt prepayment that brings total fiscal year-to-date capital return and balance sheet optimization to $30.9 million

(BUSINESS WIRE) -- Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026:

Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million.

Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million.

“Our year-to-date share repurchases and debt prepayments demonstrate our commitment to creating long-term stockholder value and our disciplined approach to capital allocation,” said Michael Perica, executive vice president and CFO, Rimini Street. “With $30.9 million already allocated to capital return and balance sheet optimization year-to-date in fiscal 2026, we have enhanced stockholder value, further reduced our debt and strengthened the balance sheet while preserving the financial flexibility to invest in our strategic growth priorities.”

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation. To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for ERP software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; our wind down of support services for Oracle’s PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States and international governments and capture new contracts with public sector entities; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on July 30, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831961587/en/

Permalink

https://www.aetoswire.com/en/news/3108202656965

Contacts

Investor Relations Contact

Dean Pohl

Rimini Street, Inc.

+1 925 523-7636

dpohl@riministreet.com

Media Relations Contact

Janet Ravin

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com